Status
Conditions
Treatments
About
The goal of this multicenter prospective longitudinal study is to study the long-term impact of multimodal treatment (chemotherapy, radiotherapy and surgery) in adult brain and base of skull tumors on neurocognitive functioning.
All included patients will complete a self-report inventory (subjective cognitive functioning, QoL, confounders), a cognitive test battery, an advanced MR at multiple timepoints. Moreover, toxicity will be scored according to the CTCAEv5.0 in these patients over time.
Full description
This study will combine MR imaging techniques together with elaborate neuropsychological assessments and RT dosimetry in 120 patients who will be examined baseline (before RT) and followed longitudinally after RT.
The first objective is to build an NTCP model for neurocognitive decline after RT (for each cognitive domain separately), linking dose-volume parameters to structures within the brain susceptible to neurological damage and neurocognitive decline after radiotherapy. These NTCP models can be used to make predictions on neurocognitive decline in future primary brain tumour patients receiving cranial RT.
The second objective is to evaluate dose-dependent neurocognitive decline. In particular, the investigators will assess:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Patients with tumours with poor prognostic characteristics:
Patients with tumours requiring craniospinal irradiation (CSI)/whole ventricular irradiation (WVI)
Hypofractionated/stereotactic radiation (fraction sizes > 2 Gy per fraction)
Inability to perform the cognitive tests or self-report inventories because of motor/sensory deficits or insufficient Dutch language proficiency
Mental retardation documented before diagnosis
Pre-diagnosis/pre-existing psychiatric diagnosis resulting in cognitive deficits like psychoses, neurodevelopmental disorders (autism/learning disorders)
Relapse previously treated by chemo and/or radiation therapy
Genetic syndrome (e.g. Down)
Unable to perform MR imaging (claustrophobia, metallic implants like pacemaker/ICD/neurostimulator)
Primary purpose
Allocation
Interventional model
Masking
120 participants in 1 patient group
Loading...
Central trial contact
Maarten Lambrecht, MD PhD; Laurien De Roeck, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal